CNTB Connect Biopharma Holdings Ltd

Price (delayed)

$2.31

Market cap

$145.45M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$100.11M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 37
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 18

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product ...

Highlights
Connect Biopharma Holdings's debt has decreased by 26% YoY
The company's gross profit has shrunk by 99% YoY
Connect Biopharma Holdings's revenue has plunged by 99% YoY

Key stats

What are the main financial stats of CNTB

CNTB stock price

How has the Connect Biopharma Holdings stock price performed over time
Intraday
3.59%
1 week
-2.94%
1 month
-6.85%
1 year
N/A
YTD
-18.09%
QTD
-11.83%

Financial performance

How have Connect Biopharma Holdings's revenue and profit performed over time
Revenue
$233,000
Gross profit
$233,000
Operating income
-$66.23M
Net income
-$64.61M
Gross margin
100%
Net margin
-27,727.9%
The company's gross profit has shrunk by 99% YoY
Connect Biopharma Holdings's revenue has plunged by 99% YoY
The operating margin has soared by 69% from the previous quarter
Connect Biopharma Holdings's net margin has surged by 68% QoQ

Price vs fundamentals

How does CNTB's price correlate with its fundamentals

Growth

What is Connect Biopharma Holdings's growth rate over time

Valuation

What is Connect Biopharma Holdings stock price valuation
P/E
N/A
P/B
3.06
P/S
560.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
429.64
The EPS has contracted by 15% from the previous quarter
The equity has contracted by 49% YoY
The price to book (P/B) is 23% higher than the last 4 quarters average of 2.4
Connect Biopharma Holdings's revenue has plunged by 99% YoY
The price to sales (P/S) is 33% lower than the last 4 quarters average of 806.6

Efficiency

How efficient is Connect Biopharma Holdings business performance
CNTB's return on invested capital has dropped by 103% since the previous quarter
The ROS has soared by 68% from the previous quarter
Connect Biopharma Holdings's ROE has decreased by 39% from the previous quarter
The company's return on assets fell by 31% QoQ

Dividends

What is CNTB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CNTB.

Financial health

How did Connect Biopharma Holdings financials performed over time
The total liabilities has soared by 78% YoY and by 24% from the previous quarter
The quick ratio has shrunk by 72% YoY and by 17% QoQ
Connect Biopharma Holdings's debt is 98% lower than its equity
Connect Biopharma Holdings's debt to equity has soared by 100% YoY
The equity has contracted by 49% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.